Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Logo for

Science 331 (6024): 1542-1545

Copyright © 2011 by the American Association for the Advancement of Science

Combining Targeted Drugs to Stop Resistant Tumors

Jocelyn Kaiser

In the past few years, researchers have reported dramatic responses to a handful of new drugs that are given to cancer patients with a specific mutation in their tumors. But although these drugs can shrink solid tumors and extend patients' lives, for reasons that are still not well understood, they never completely eliminate the cancer. Researchers are seeking to identify the ways that tumors resist the drug, then find or develop second-generation drugs that block these escape routes so they can design a cocktail—perhaps two, three, or more drugs—that, if given when a patient is first diagnosed, could stop tumors from ever evading the blockade. This approach has worked for patients infected with HIV, who usually take three antiviral drugs, and many researchers say there's no reason it shouldn't work for cancer. But even if a combination therapy stops tumor growth, it may not buy patients more than a temporary reprieve, researchers admit. To stretch the benefit over years, it might be necessary to devise one complex cocktail after another, each tailored to a patient's evolving tumors.

Network-based drug discovery by integrating systems biology and computational technologies.
E. L. Leung, Z.-W. Cao, Z.-H. Jiang, H. Zhou, and L. Liu (2013)
Brief Bioinform 14, 491-505
   Abstract »    Full Text »    PDF »
Conquering Cancer in Our Lifetime: New Diagnostic and Therapeutic Trends.
E. P. Diamandis, R. C. Bast Jr., and C. Lopez-Otin (2013)
Clin. Chem. 59, 1-3
   Full Text »    PDF »
Electron transfer-based combination therapy of cisplatin with tetramethyl-p-phenylenediamine for ovarian, cervical, and lung cancers.
T. Luo, J. Yu, J. Nguyen, C.-R. Wang, R. G. Bristow, D. A. Jaffray, X. Z. Zhou, K. P. Lu, and Q.-B. Lu (2012)
PNAS 109, 10175-10180
   Abstract »    Full Text »    PDF »
Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?.
P. Borst (2012)
Open Bio 2, 120066
   Abstract »    Full Text »    PDF »
MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells.
C.-T. Chen, H. Kim, D. Liska, S. Gao, J. G. Christensen, and M. R. Weiser (2012)
Mol. Cancer Ther. 11, 660-669
   Abstract »    Full Text »    PDF »
Finding a Panacea among Combination Cancer Therapies.
R. Yamaguchi and G. Perkins (2012)
Cancer Res. 72, 18-23
   Abstract »    Full Text »    PDF »
Vemurafenib (PLX4032): An Orally Available Inhibitor of Mutated BRAF for the Treatment of Metastatic Melanoma.
Y. Heakal, M. Kester, and S. Savage (2011)
Annals of Pharmacotherapy 45, 1399-1405
   Abstract »    Full Text »    PDF »

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882